“Reduce APOE” is an oversimplified view. The mechanisms by which the AD-associated E4 genotype (arg112, arg158) results in disease are still poorly understood. The main therapeutic hypothesis for AD is to reduce the levels of pathogenic plaques and aggregates using antibodies.